Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren't Buying It
What happened
Silicon Valley firms are touting AI as a game‑changing tool that could dramatically speed up drug discovery and even cure diseases, but executives at major pharmaceutical companies remain skeptical, citing concerns about data quality, regulatory hurdles, and the technology’s current limitations. While AI can help identify promising compounds and predict outcomes, drugmakers say the hype outpaces proven results and they are waiting for more concrete, reproducible successes before committing large investments.
Why it matters
The disconnect highlights that AI’s impact on pharma will likely be incremental rather than revolutionary in the near term, prompting startups to focus on partnership models that demonstrate clear, validated value. This cautious stance may temper investor enthusiasm and shape the pace at which AI-driven drug development tools are adopted across the industry.
Is this a big deal?
Get stories like this every morning
The day's AI news in plain English, in your inbox at 8:30 IST. Free.
More AI news
Show HN: New Cartesia Text-to-Speech ModelIndustry news · 13 Nov 2026Chicago schools to Google – we'd rather lose Search than be forced to accept AIIndustry news · 13 Nov 2026Introducing ChatGPT WalletOpenAI · 13 Nov 2026Shield helps technicians hand off legacy portal work with OpenAIOpenAI · 13 Nov 2026How AI Is Helping Care Teams Get Patients the Right Care, SoonerNVIDIA · 13 Nov 2026This page was collected from wsj.com and summarised automatically by AIPulsee's pipeline. See how it runs.